Skip to main content
. 2022 Dec 20;20:492. doi: 10.1186/s12916-022-02673-x

Table 3.

Associations between PPI exposure at different timepoints during pregnancy and maternal and neonatal health outcomes expressed as odds ratios (OR) with 95% confidence interval (CI) obtained by multiple logistic regression including all live births

PPI use Pre-eclampsia GDM Preterm AS5min < 7 SGA LGA
Overall 1.19 (1.10–1.29) 1.29 (1.16–1.43) 1.23 (1.14–1.32) 1.07 (0.93–1.22) 1.27 (1.16–1.40) 0.84 (0.77–0.91)
Before pregnancy (3 months) 0.92 (0.79–1.06) 1.07 (0.88–1.30) 1.26 (1.12–1.42) 1.13 (0.89–1.44) 1.42 (1.11–1.82) 0.89 (0.71–1.12)
First trimester 0.91 (0.78–1.05) 1.20 (0.99–1.46) 1.16 (1.02–1.30) 1.06 (0.85–1.34) 1.25 (1.00–1.57) 0.81 (0.66–1.00)
Second trimester 1.38 (1.16–1.65) 0.97 (0.80–1.18) 1.58 (1.40–1.78) 1.15 (0.93–1.43) 1.06 (0.84–1.33) 0.87 (0.70–1.08)
Third trimester 1.45 (1.20–1.76) 1.20 (1.00–1.45) 0.54 (0.47–0.61) 0.84 (0.66–1.06) 0.85 (0.63–1.13) 0.79 (0.62–1.01)
Before/first trimester* 0.62 (0.42–0.90) 1.28 (0.90–1.80)
Second/third trimester** 0.64 (0.49–0.85) 1.46 (0.98–2.16) 1.41 (1.00–2.00)

*Interaction term for PPI use 3 months before pregnancy and during the first trimester

**Interaction term for PPI use in second and third trimesters of pregnancy

Abbreviations: AS5min, Apgar score 5 min after birth; GDM, gestational diabetes; LGA, large for gestational age; PPI, proton pump inhibitor; SGA, small for gestational age